周文其

周文其 ,M.D.
單位: 林口長庚醫院
現職: 林口長庚醫院腫瘤科主治醫師
聯絡地址: 桃園市龜山區復興街五號
電話: 03-328-1200

研究領域:

• 癌症

工作經歷:

林口長庚紀念醫院 血液腫瘤科 主治醫師

學歷:
1993-2000 台北醫學院 醫學系
2011- 迄今 長庚大學 醫學院 博士班

代表論文:

1. Chou WC, Lu CH, Lin G, Hung YS, Chen PT, Hsu CH, Chen JS, Yeh KY, Wang HM, Liaw CC*. Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center. Support Care Cancer. 2007;15(10):1185-1190. 
2. Chou WC, Hung YS, Hsu JT*, Chen JS, Lu CH, Hwan TL, Rau KM, Yeh KY, Chen TC, Sun CF. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95:344-350.
3. Chou WC, Hung YS, Kao CY, Su PJ, Hsieh CH, Chen JS, Liau CT, Lin YC, Liaw CC, Wang HM*. Impact of palliative care consultative service on disease awareness for patients with terminal cancer. Support Care Cancer. 2013 Jul;21(7):1973-81
4. Chou WC, Lai YT, Huang YC, Chang CL, Wu WS, Hung YS*. Comparing end-of-life care for hospitalized patients with chronic obstructive pulmonary disease and lung cancer in Taiwan. J Palliat Care. 2013;29(1):29-35.

5. Chou WC, Chang CL, Liu KH, Hsu JT, Cheng WH, Hsu HC, Shen WC, Hung YS, Chen JS. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment. World J Surg Oncol. 2013;11:310.

所有論文著作一覽表

學會與認證:

2003 內科醫學會
2005 腫瘤醫學會
2008 Bord of Taiwan Society of Cancer Palliative Medicine
2009 Lecturer

目前進行中的研究計劃:
1 ) 2013/4- 2015/3 A randomized, phase ii, placebo controlled study of gdc-0068, an inhibitor to akt, in combination with fluoropyrimidine plus oxaliplatin in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
2 ) 2012/1-2014/12 Application of Ga-68 DOTATOC in Patients with Neuroendocrine Tumors.
3 ) 2012/5 -2017/11 A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin -RADIANT-4
4 ) 2012/9- 2017/5 The Clinical Significance of Extracellular Matrix/Integrin and TGF Signaling Pathway Biomarkers in Patients with Pancreatic Cancer
5 ) 2012/10- 2017/12 A randomized, multicenter, adaptive phase ii/iii study to evaluate the efficacy and safety of trastuzumab emtansine (t-dm1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic her-2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction .